UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
|
| |||
| ||||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| ||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
Item 5.02 | Election of Directors |
On August 13, 2020, Kadmon Holdings, Inc. (the "Company") announced the appointment of Nancy Miller-Rich to its Board of Directors (the "Board"). Ms. Miller-Rich has 35 years of experience in the pharmaceutical industry, having served as a consultant to several biopharmaceutical companies and healthcare organizations and held management positions at Merck and Schering-Plough. Ms. Miller-Rich has been appointed to serve for a term expiring at the Company's 2021 Annual Meeting of Stockholders and until her successor has been elected and qualified, or until her earlier resignation or removal.
Consistent with the Company's non-executive director compensation policy, Ms. Miller-Rich will receive an annual retainer of $50,000 per annum, which will be prorated from the date of Ms. Miller Rich’s appointment to the Board. In addition, Ms. Miller-Rich has been granted an option to purchase 36,364 shares of the Company's common stock at an exercise price of $4.17 per share, the closing market price of the Company’s common stock on the date of grant, which shall vest in equal annual installments over three years.
There are no arrangements or understandings between Ms. Miller-Rich and any other person pursuant to which Ms. Miller-Rich was selected as a director, and there are no transactions in which the Company is a party and in which Ms. Miller-Rich has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
Item 7.01 | Regulation FD Disclosure |
On August 13, 2020, the Company issued a press release announcing Ms. Miller-Rich’s appointment to the Board.
The information in this Item 7.01, including Exhibit 99.1 hereto, is being "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.
The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
|
|
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
|
| Description |
99.1 | Press release, dated August 13, 2020, issued by Kadmon Holdings, Inc. |
|
|
|
|
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kadmon Holdings, Inc. |
|
|
| ||
Date: August 13, 2020 |
|
|
| /s/ Harlan W. Waksal |
|
|
|
| Harlan W. Waksal |
|
|
|
| President and Chief Executive Officer |